Histology Coding ANSWERS

Similar documents
Quiz. b. 4 High grade c. 9 Unknown

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?

SEER Summary Stage Still Here!

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

Exercise. Discharge Summary

FINALIZED SEER SINQ S NOVEMBER 2011

Thyroid and Adrenal Gland

Q: In order to use the code 8461/3 (serous surface papillary) for ovary, does it have to say the term "surface" on the path report?

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue

8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank

FINALIZED SEER SINQ QUESTIONS

Carcinoma of the Urinary Bladder Histopathology

2007 New Data Items. Slide 1. In this presentation we will discuss five new data items that were introduced with the 2007 MPH Coding Rules.

A Practicum Approach to CS: GU Prostate, Testis, Bladder, Kidney, Renal Pelvis. Jennifer Ruhl, RHIT, CCS, CTR Janet Stengel, RHIA, CTR

Uterine Malignancies. Collecting Cancer Data: Uterine Malignancies 10/7/2010. NAACCR Webinar Series 1. Questions. Fabulous Prizes!!!

A patient with recurrent bladder cancer presents with the following history:

EVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013

11/21/13 CEA: 1.7 WNL

NAACCR Webinar Series 1 Q&A. Fabulous Prizes. Collecting Cancer Data: Ovary 11/3/2011. Collecting Cancer Data: Ovary

FINALIZED SEER SINQ QUESTIONS

NAACCR Webinar Series /7/17

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS

Kyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System

DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #

New Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%

Case Scenario 1: Thyroid

ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *

Case Scenario 1. 1/2/13 History: 64-year-old white female presented with right leg swelling and redness, abdominal pain.

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series

FINALIZED SEER SINQ QUESTIONS April July, 2017

Quiz 1. Assign Race 1, Race 2 and Spanish Hispanic Origin to the following scenarios.

UTERINE SARCOMA EXAMPLE OF A UTERINE SARCOMA USING PROPOSED TEMPLATE

Uterus Malignancies /5/15

Testicular Malignancies /8/15

CAP Cancer Protocol and ecc Summary of Changes for August 2014 Thyroid Agile Release

Multiple Primary Quiz

Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.

Neoplasms of the Prostate and Bladder

A215- Urinary bladder cancer tissues

Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES CASE 1: FEMALE REPRODUCTIVE

Case Scenario 1. 1/2/13 History: 64-year-old white female presented with right leg swelling and redness, abdominal pain.

FINALIZED SEER SINQ QUESTIONS

Interactive Staging Bee

Case Scenario 1. History

Boot Camp Case Scenarios

Guidelines for Assigning Summary Stage 2000

Staging and Treatment Update for Gynecologic Malignancies

Bladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)

Endometrial Cancer. Incidence. Types 3/25/2019

Definition of Synoptic Reporting

Urinary Bladder: WHO Classification and AJCC Staging Update 2017

Coding Pitfalls 9/1/2011. Coding Pitfalls Questions. Fabulous Prizes!!! September 1, NAACCR Webinar Series 1

Radiation Oncology MOC Study Guide

MCR: MANAGEMENT OF 2018 CHANGES. By: Maricarmen Traverso-Ortiz MPH, CGG, CTR

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX

Quiz The main functions of the ovaries are a. To produce oocytes b. To produce estrogen c. To produce progesterone d.

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

Abstracting Upper GI Cancer Incidence and Treatment Data Quiz 1 Multiple Primary and Histologies Case 1 Final Pathology:

Summary Stage 2018 (SS2018)

Prostate Case Scenario 1

What is endometrial cancer?

5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.

What s New for 8 th Edition

Case Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.

Collaborative Stage. Site-Specific Instructions - LUNG

Cervical Cancer 3/25/2019. Abnormal vaginal bleeding

Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04

Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04

A301 VI- Various cancer tissues with corresponding normal tissues

Pancreas Case Scenario #1

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Quiz 1: Terminology and Anatomy

Kieran Sultan, PGY4 Penrose St. Francis Hospital

Major Rule Changes. Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging

Completing the Puzzle AJCC TNM Staging Breast. Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017

1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ 2 Primary Site (291) = C711 Date of Diagnosis (283) =

uterine cancer endometrial cancer

Pancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)

Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.

Staging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion

Case Scenario. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

Interactive Discussion of Part I CS Coding Instructions: Working the Cases

Management guideline for patients with differentiated thyroid cancer. Teeraporn Ratanaanekchai ENT, KKU 17 October 2007

Janjira Petsuksiri, M.D

Page # 1. Endometrium. Cellular Components. Anatomical Regions. Management of SIL Thomas C. Wright, Jr. Most common diseases:

2007 Multiple Primary and

QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX

Coding Pitfalls 9/11/14

2018 Grade PEGGY ADAMO, RHIT, CTR OCTOBER 11, 2018

FINALIZED SEER SINQ S MAY 2012

Case Scenario 1. Pathology: Specimen type: Incisional biopsy of the glottis Histology: Moderately differentiated squamous cell carcinoma

FINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma

2018 New Grade Coding Rules It s a Good Thing!

Transcription:

Histology Coding ANSWERS 1.) Biopsy of a right thyroid nodule reveals papillary carcinoma. What is the ICD-O-3 code? a. 8050/3 - Papillary carcinoma b. 8260/3 - Papillary adenocarcinoma Rationale/comment: per MPH Other Sites Histology coding rules, MPH Rule 14 clarifies if the primary site is thyroid and the histology is papillary carcinoma, always code to papillary adenocarcinoma. The thyroid is a gland, and adenocarcinoma reflects a carcinoma which arises in glandular tissue. 2.) Ductal or Ductular are synonyms for ductal carcinoma. a. True b. False Rationale/Comment: Ductular ca is a malignancy that is infrequently found in the breast. Code 8521 Ductular ca is seldom applied to the breast, although the ICD-O-3 site associated code (C50._) which appears after this code can be misleading. See MPH Breast Terms and Definitions. You would more commonly see a Ductular ca in Pancreas, biliary ducts or prostate. 3.) What is the histology code for micropapillary carcinoma of the Thyroid? a. 8341/3 papillary microcarcinoma b. 8260/3 papillary adenocarcinoma Rationale/Comment: The term micropapillary does not refer to a specific histologic type. It means the papillary portion of the tumor is minimal or occult (1cm or less in diameter). According to SEER SINQ 20150023 if the primary is thyroid and the pathology states papillary microcarcinoma or micropapillary carcinoma, code to 8260 not 8341. This applies to micropapillary carcinoma s of the thyroid only. 4.) Which of the following is an alternate name for diffuse large B-cell lymphoma (DLBCL). Circle any that apply a. Splenic EBV-associated B-cell lymphoproliferative disorder b. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma c. Double hit lymphoma d. b & c e. All of the above Rationale/Comment: Per Heme Database-All are coded to histology 9680/3 5.) What is the correct histology code for Follicular lymphoma grade 1-2? a. 9690/3 Follicular Lymphoma NOS b. 9695/3 Follicular Lymphoma grade 1 c. 9691/3 Follicular lymphoma grade 2

Rationale/Comment: Per SINQ 20130065 when there is a grade such as 1-2 indicated, take the histology associated with the higher grade disease process, even though the lower grade histology code is higher. 6.) Patient diagnosed with high grade endometrioid adenocarcinoma with squamous differentiation. What is the correct histology code? a. 8560/3-Adenosquamous carcinoma b. 8380/3- Endometrioid Adenocarcinoma c. 8570/3-Adenocarcinoma with squamous metaplasia Rationale/Comment: Endometrioid Adenocarcinoma, combined with squamous metaplasia or squamous differentiation is coded to Adenoca with squamous metaplasia 8570/3. Reference SINQ 20110014. NOTE: I highly recommend you update the GYN table in your MPH manual (as recommended in the above SINQ) with this combo Column 1: Required Histology Column 2: Combined with Histology Column 3: Combination Term Endometrioid Squamous metaplasia Adenocarcinoma with Adenocarcinoma Squamous differentiation squamous metaplasia This will be added to the updated MPH manual when released in 2018. Column : Code 8570 7.) Site Corpus Uteri. Histology is papillary serous adenocarcinoma. What is the correct histology code? a. 8323/3 b. 8260/3 c. 8460/3 Rationale/Comment: Use MP/H Rule 11 Code the histology when only ONE histology type is identified. Papillary Serous Adenocarcinoma, while it is a mixed histology, it already has it s own specific ICD-O-3 code. The rule is always code the specific mixed ICD-O-3 code if one is available BEFORE coding to a combo/mixed histology code found in the MPH GYN Table 2 (MPH Other Sites). Do not code to 8323. 8.) Site Corpus Uteri: Histology is Endometrioid and clear cell carcinoma. What is the correct histology code? a. 8323/3 b. 8380/3 c. 8310/3 Rationale/Comment: Using MP/H rule H16, these are multiple specific Histologies, therefore using GYN table 2, this is coded to Mixed cell adenocarcinoma, 8323.

Multiple Primary & Histology 1.) Lung Left upper lung lobectomy reveals two tumor: #1) 1.2cm Adenocarcinoma, poorly differentiated (Grade 3), confined to lung. #2) 0.9cm Adenocarcinoma, well-differentiated (grade 1), confined to lung. Pathology Comment: The two tumors, although both adenocarcinoma, show markedly different histologies and are considered synchronous primaries. Multiple synchronous primaries are staged separately according to the 7 th edition AJCC. How many primaries should be reported? One Which MPH rule is used? Stop at rule M12. The patient has two tumors in the same lung with the same histology. COMMENT: Do not use the AJCC Manual to make multiple primary decisions. Use the MP/H Rules to determine the number of primaries to accession. Reference SEER SINQ: 20130054 2.) Bladder 1/5/15 Bladder base tumor identified on cystoscopy; biopsied. Pathology reveals urothelial carcinoma in situ. PE: Abdomen no palpable masses. H&P otherwise WNL. Treatment plan is TURBT on 1/23/15. 1/18/15 Progress Note: Patient canceled scheduled surgery due to her mother s death. She will be out of state handling the estate and will reschedule upon her return. 3/1/2016 CT Ab/pelvis: Bladder size normal, no evidence of bladder wall thickening or suspicious LAD. 3/8/15 TURBT: All visible tumor removed with bx of M.P. Pathology: High grade urothelial carcinoma within fragments of fibrovascular tissue and smooth muscle with chronic inflammation and fibrosis at the deep margin. MD TNM Clinical stage is ct2 cn0 cm0 Stage II. How many primaries should be reported. Two (CORRECTION ONE TUMOR) Which MP/H rule is used? M2 Comment: Patient had a biopsy on 1/5/15 confirming malignancy, followed by the TURBT on 3/8/15- this is one tumor. IF, the scenario had indicated on 1/5/15 the patient had a cystoscopy, bx and TURBT, revealing urothelial carcinoma in situ, followed by another TURBT on 3/8/15 revealing an invasive tumorthat would be two primaries using M5- an insitu tumor followed by an invasive tumor more than 60 days apart. 3.) Thyroid 1/5/10 Left thyroid lobectomy for follicular carcinoma 4/10/10 Right thyroid lobectomy, papillary carcinoma, follicular variant. How many primaries should be reported? Two Which MP/H rule is used? M17 Reference SINQ 20091027 Comment: For Thyroid, using the Other Sites section, these are separate primaries based on their ICD-O-3 histology codes. Follicular ca is 8330 and Papillary Ca follicular variant is 8340. And because the tumors were diagnosed more than 60 days apart, Rule M6 does not apply.

4.) Breast Right breast lumpectomy. Pathology: Multifocal breast cancer demonstrating one 0.8 cm infiltrating ductal carcinoma in the right UOQ, moderately differentiated, with a second 0.5 cm infiltrating ductal ca, moderately differentiated, as well as a 1.9 cm area of intraductal carcinoma. Lumpectomy margins including deep margins are clear. How many primaries should be reported? One Which MP/H rule is used? M11 COMMENT: Multiple intraductal and/or duct carcinoma s are a single primary. And these are all in the same breast quadrant. 5.) Colon Sigmoidcolectomy reveals a large colon polyp and 2cm adjacent but separate from the polyp is a 1.8 cm sessile friable tumor. Pathology reveals focal invasive adenocarcinoma in a tubulovillous adenoma, as well as a 2.2cm moderately differentiated adenocarcinoma extending into the musuclaris propria. 0/22 lymph nodes are positive. No perineural invasion. CRM negative by 4cm. How many primaries should be reported? One Which MP/H rule is used? M7 COMMENT: A frank (obvious tumor) invasive or in situ carcinoma, AND an in situ or invasive tumor in a polyp, are a single primary when they are within the same segment of the colon. If they were in different segments such as sigmoid and descending, then that would be two primaries.

Site Specific Factors Quiz LUNG Patient has 1.2cm RUL Adenocarcinoma, and a 2.2cm RML squamous cell carcinoma of the lung. 1.) How should you code SSF1- Separate tumor nodules-ipsilateral lung a. 000 No separate tumor nodules b. 010 Separate tumor nodules in ipsilateral lobe, same lung c. 020 separate tumor nodules in ipsilateral lobe, different lobe Rationale/Comment: These are two separate tumors/primaries based on histology and MPH rules. They are also considered synchronous primaries per AJCC TNM rules and are staged separately. Thus for each abstract the other tumor nodule is not considered when coding SSF1 and should be coded 000. 2.) If you have a lung cancer with multiple pulmonary nodules in the right lung upper lobe, middle lobe and lower lobe, and biopsy of one of the pulmonary nodules in the Upper lobe is positive for carcinoma, would you consider all the described pulmonary nodules to be malignant when coding SSF 1? a. Yes b. No ENDOMETRIUM #1 TAH/BSO: HG serous adenoca of endometrium, 12cm, tumor invading 99% of myometrium, +LVI. Lt fallopian tube involved by met serous adenoca on the surface. Cervix neg. 1/5 obturator LNs pos; 2/15 pelvic LNs positive; 0/1 common iliac LN pos. 1/5 para-aortic LNs positive 3.) What is SSF 2 Peritoneal Cytology a. 000 b. 010 c. 997 d. 998 e. 999 Rationale: PER CS V02.05 Part 1; Recording Lab Test and Tumor Markers: Use code 999 when there is no mention of pelvic wash. Without a statement pelvic wash was done, or negative, you cannot presume it was done and/or negative. http://cancerbulletin.facs.org/forums/forum/collaborative-stage/lung-and-otherrespiratory/lung/8966-pulmonary-nodules-vs-tumor-nodules http://cancerbulletin.facs.org/forums/forum/collaborative-stage/female-genital-system/corpuscarcinoma/1513-site-specific-factor-2-peritoneal-cytology (#4 and #5)

4.) What is SSF 3- Number of Positive Pelvic LNs: 003 Rational: 1/5 obturator LNs, 2/15 pelvic LNs and 0/1 common iliac LNs. Note: Obturator & Common iliac LNs are also pelvic LNs (so are internal/hypogastric LNs, paracervical, presacral, parametrial, and external iliac). 5.) What is SSF 4 Number of Examined Pelvic LNs: 021 Rationale: 1/5 obturator LNs pos; 2/15 pelvic LNs positive; 0/1 common iliac LN pos; all at left are pelvic LNs. 6.) What is SSF 5 Number of Positive Para-Aortic LNs: 001 Rationale: 1+/5 para-aortic LNs 7.) What is SSF 6 Number of Examined Para-Aortic LNs: 005 Rationale: 5 para-aortic LNs examined. 8.) What is number of Regional LNs positive? 04 Rationale: 1/5 obturator LNs pos; 2/15 pelvic LNs positive; 0/1 common iliac LN pos, 1/5 para-aortic LNs pos. Para-aortic LNs are also regional LNs, and should be included in the regional LN positive total count. 9.) What is the number Regional LNs examined? 26 Rationale: Para-aortic LNs are also regional nodes and should be included in the total count for nodes examined. 1/5 obturator, 2/15 pelvis, 0/1 common iliac, 1/5 para-aortic LNs. ENDOMETRIUM #2 TAH/BSO, tumor debulking, omentectomy and lymphadenectomy: 3cm mixed cell adenoca (mostly highgrade serous ca w/minor endometrioid adenoca) in endometrium, invades inner half/47% of myometrium 0.7cm deep; involving parametrium, fundus, body, lower uterine segment, cervical stroma, peritoneum, omentum, ovaries, tubes. LVI neg. 2/32 LNs positive. 10. What is SSF 3- Number of positive pelvic LNs? 002 02/32 LNs pos 11. What is SSF 4- Number of examined pelvic LNs? 032 02/32 LNs pos For #10 and #11 Since the LNs were not defined as pelvic vs para-aortic presume the LNs removed are at least pelvic regional LNs and code under SSF #3 and SSF #4. See CAnswer Forum reference below.

12. What is SSF 5- Number of positive Para-Aortic LNs? 999 13. What is SSF 6- Number of examined Para-aortic LNs? 999 For #12 and #13, It is unknown if any of the LNs submitted were para-aortic, therefore code SSF5 and SSF6 to 999/unknown. 14. What is the number of Regional LNs positive? 02 15. What is the number of Regional LNs examined? 32 For #14 and #15 Regional Nodes Pos/Examined, code the path totals of 02/32 pelvic LNs pos; since both pelvic and para-aortic LNs are regional it does not matter that we do not know if any were pelvic vs para-aortic or a combination of both. http://cancerbulletin.facs.org/forums/forum/collaborative-stage/female-genital-system/corpuscarcinoma/6432-ssf-3-4-5-6-when-not-stated-if-pelvic-or-para-aortic ENDOMETRIUM #3 The lymph node involvement for a uterine cancer was documented in pathology as: 0/5 Rt pelvic LNs, 0/2 Rt common iliac and para-aortic LNs pos, 0/3 L pelvic LNs pos, and 0/4 L common and para-aortic LNs pos. 15.) What is SSF3- Number of positive pelvic LNs? 000 Rationale: All the LNs sampled were negative so we can code 000 negative even though the pelvic/para-aortic LNs were combined in descriptions and it is not clear how many there were of each. 16.) What is SSF 4 Number of examined pelvic LNs? 097 Rationale: We know pelvic LNS were resected but we don t know how many since references to the common iliac and the para-aortic were combined- code 997. 17.) What is SSF 5- Number of positive Para-aortic LNs? 000 Rationale: All the LNs sampled were negative including the references to para-aortic LNs. 18.) What is SSF 6- Number of examined Para-aortic LNs? 097 Rationale: We know para-aortic LNS were resected but we don t know how many- code 097. 19.) What is the number of regional LNs positive? 00 Rationale: All the nodes sampled were negative and all are regional nodes.

20.) What is the number of regional LN examined? 14 Rationale: Combined total of all LNs resected =14 pelvic and para-aortic LNs are all regional LNs. http://cancerbulletin.facs.org/forums/forum/collaborative-stage/female-genital-system/corpuscarcinoma/727-coding-of-ssf-3-4-for-endometrial-cases TESTIS Patient diagnosed with testicular cancer. Tumor markers at diagnosis were Alpha-fetoprotein: 2628 ng/ml (normal range 0-15 ng/ml), beta-hcg: 696 IU/ml (normal range 2-5 IU/ml), LDH: 936 U/L (normal range 300-600 U/L). Patient underwent orchiectomy. Three weeks post orchiectomy serum tests AFP and Beta-hCG dropped to within normal range, but the LDH continued to be elevated (920 IU/L norm 300-600). Patient began a chemotherapy regimen of BEP (Bleomycin, Etoposide, and Cisplatin) on 9/28/14. The LDH Serum markers normalized after completion of the 1st round of chemotherapy noted on 11/2/14 with an LDH of 229 IU/L (norm 300-600). 21.) What is the SSF13? 000 Rationale: Post orchiectomy the AFP was noted to be within the normal range ; even without the value we can code to 000 within normal limits. 22.) What is SSF 15? 000 Rationale: Post orchiectomy the hcg was noted to be within the normal range ; even without the value we can code to 000 within normal limits. 23.) What is SSF 16? 920IU/L = Code 020 (Range (S2) 1.5 x 10 x N (between 1.5 and 10 times the upper limit of normal for LDH Rationale: See Note #2 for CS SSF16 Record the range of the LDH text as documented in the patient record after orchiectomy and prior to further treatment. The post orchiectomy value was 920 and this was prior to further treatment with chemotherapy. The LDH value of 229 IU/L after completion of chemotherapy should not be used. THYROID 55-year old female presents with left neck mass. Exam reveals a 3.0cm mass just lateral to the thyroid, most likely matted lymph nodes. Neck US: 4.4cm soft tissue mass, likely neoplastic; likely representing thyroid malignancy and LN conglomeration. Right thyroid lobe reveals two nodules, one 2.0cm and one 1.4cm. CXR/CT Chest: Negative. Patient undergoes total thyroidectomy with left neck dissection. Pathology reveals papillary carcinoma in the left lobe 2.3 cm with extrathyroidal extension. Right lobe negative; 7+/8 central compartment LNs pos; 1+/3 retropharyngeal LNs. 3+/6 perithyroidal LNs pos. 24.) What is SSF 1- Solitary vs Multifocal tumor? 010 Solitary Tumor

Rationale: There is a single 2.3 cm tumor in the left lobe on pathologic exam. The nodules in the right lobe noted on US should not be interpreted as multiple tumor foci. Tumor multifocality can only be determined based on pathologic exam of the tumor. 25.) What is the number of Regional Nodes Positive? 11 26.) What is the number of Regional Nodes Examined? 17 Rationale/Comment for #25 and #26: All the named lymph nodes are regional LNs for thyroid. Central compartment LNs are Level VI LNs which is the most common site for LN mets in thyroid. Parathyroid or Perithyroidal LNs are also level VI LNs and are not lymph nodes specific to the parathyroid gland- be sure to include them in regional LNs counts.